FDA Approves $2.125 Million Gene Therapy From Novartis

Credit: Wochit News
Published on May 25, 2019 - Duration: 00:31s

FDA Approves $2.125 Million Gene Therapy From Novartis

Reuters reports that the Swiss drugmaker Novartis has secured U.S. approval for its gene therapy "Zolgensma".

The therapy is used to treat spinal muscular atrophy (SMA).

Which is the leading genetic cause of death in infants.

The U.S. Food and Drug Administration approved Zolgensma for pediatric patients under age 2 with SMA, including those not yet showing symptoms. The drugmaker has reportedly priced the one-time treatment at a record $2.125 million.

Advertisement

FDA Approves $2.125 Million Gene Therapy From Novartis

OCT.

25, 2011 FILE PHOTO AP FILE PHOTO OF AUG.

13, 2016 Available for all permitted uses under our |License Terms|.

, Model released THURSDAY, AUG.

2, 2018, FILE PHOTO Available for all permitted uses under our |License Terms|.

, Model and property released AP PROVIDES ACCESS TO THIS THIRD PARTY PHOTO SOLELY TO ILLUSTRATE NEWS REPORTING OR COMMENTARY ON FACTS DEPICTED IN IMAGE; MUST BE USED WITHIN 14 DAYS FROM TRANSMISSION; NO ARCHIVING; NO LICENSING; MANDATORY CREDIT

You are here

Recent related videos from verified sources

Newt Gingrich on Politics, Biotech, and Investing Advice 11:26
Credit: The Street - Published 4 hours ago 

FDA approves new gene therapy for Spinal Muscular Atrophy 02:26
Credit: Idaho On Your Side - Published on May 31, 2019 

Gene therapy offers help for chronic pain in dogs 02:22
Credit: TODAY’S TMJ4 - Published on May 29, 2019 

FDA Approves Gene Therapy Drug That Costs $2.1 Million 00:52
Credit: Geo Beats - Published on May 25, 2019 

You might like